190 related articles for article (PubMed ID: 22644089)
1. Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.
Omair MA; Alnaqbi KA; Lee P
Clin Rheumatol; 2012 Aug; 31(8):1259-61. PubMed ID: 22644089
[TBL] [Abstract][Full Text] [Related]
2. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
4. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis.
Giardina AR; Ferrante A; Ciccia F; Impastato R; Miceli MC; Principato A; Triolo G
Rheumatol Int; 2010 Sep; 30(11):1437-40. PubMed ID: 19851772
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
Ren L; Li J; Luo R; Tang R; Zhu S; Wan L
Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113
[TBL] [Abstract][Full Text] [Related]
6. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
[TBL] [Abstract][Full Text] [Related]
7. [Biologicals in the treatment of rheumatic diseases].
Scherer HU; Burmester GR
Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
[No Abstract] [Full Text] [Related]
8. Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis.
Capkin E; Karkucak M; Kose MM; Çakmak VA; Turkyilmaz AK; Tosun M
Rheumatol Int; 2012 Feb; 32(2):431-4. PubMed ID: 21120488
[TBL] [Abstract][Full Text] [Related]
9. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice.
Arends S; van der Veer E; Kamps FB; Houtman PM; Bos R; Bootsma H; Brouwer E; Spoorenberg A
Clin Exp Rheumatol; 2015; 33(2):174-80. PubMed ID: 25797228
[TBL] [Abstract][Full Text] [Related]
10. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.
Serac G; Tubach F; Mariette X; Salmon-Céron D; Ravaud P; Lioté F; Laharie D; Ziza JM; Marguerie L; Bonnet C; Falgarone G; Nicolas N; Lortholary O; Chosidow O
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):726-9. PubMed ID: 22113472
[No Abstract] [Full Text] [Related]
11. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
[TBL] [Abstract][Full Text] [Related]
12. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
[No Abstract] [Full Text] [Related]
13. [TNF inhibitors for treatment of rheumatoid arthritis].
Otomo K; Koike T
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2405-12. PubMed ID: 19149036
[No Abstract] [Full Text] [Related]
14. [Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].
Andreu JL; Otón T; Sanz J
Reumatol Clin; 2011; 7(1):51-5. PubMed ID: 21794779
[TBL] [Abstract][Full Text] [Related]
15. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.
Kristensen LE; Petersson IF; Geborek P; Jöud A; Saxne T; Jacobsson LT; Englund M
Rheumatology (Oxford); 2012 Feb; 51(2):243-9. PubMed ID: 21565900
[TBL] [Abstract][Full Text] [Related]
16. Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases.
Theibich A; Dreyer L; Magyari M; Locht H
Clin Rheumatol; 2014 May; 33(5):719-23. PubMed ID: 24202614
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab for the treatment of ankylosing spondylitis.
Sieper J; Rudwaleit M; Braun J
Expert Opin Pharmacother; 2007 Apr; 8(6):831-8. PubMed ID: 17425478
[TBL] [Abstract][Full Text] [Related]
18. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab.
Cohen JD; Ferreira R; Jorgensen C
J Rheumatol; 2011 Jul; 38(7):1527. PubMed ID: 21724733
[No Abstract] [Full Text] [Related]
19. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
Ramos-Casals M; Brito-Zerón P; Muñoz S; Soria N; Galiana D; Bertolaccini L; Cuadrado MJ; Khamashta MA
Medicine (Baltimore); 2007 Jul; 86(4):242-251. PubMed ID: 17632266
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]